RE49444 Scope and Claims Map: US Patent Landscape for 80 μg [Glu22,25, Leu23,28,31, Aib29, Lys26,30]hPTHrP(1-34)NH2 Osteoporosis Methods (Subcutaneous, Pen, Buffer/pH, Antimicrobial, PK Targets)
What is US patent RE49444 and what does it cover in practice?
US RE49444 is a reissue patent that redirects the patent estate around specific daily subcutaneous dosing of an engineered human PTHrP(1-34) analog at 80 μg, with claim scope anchored to:
- Dose: 80 μg of the specified peptide.
- Route and regimen: daily subcutaneous administration to a human with osteoporosis.
- Product/solution constraints: buffer identity and pH window and, in dependent claims, anti-microbial package, multi-dose injection pen, and measured stability/PK outcomes.
- Pharmacokinetic target windows: claims lock into specific Cmax/Tmax/t1/2/AUC ranges for post-menopausal women and dosing regimens.
- Process constraint: a formulation process includes dissolution in water and filtration through a 0.2 μm filter.
The practical effect is that RE49444 is not just “method of treating osteoporosis with a peptide.” It is a tight combination of clinical regimen + formulation parameters + device format + PK/stability metrics, which can make around-designs harder when competitors match both the dose/route and the formulation envelope.
What are the independent claims in RE49444 and how broad are they?
Claim 1 (independent)
- A method of treating osteoporosis comprising daily subcutaneous administration of a composition comprising 80 μg of [Glu22,25, Leu23,28,31, Aib29, Lys26,30]hPTHrP(1-34)NH2 to a human in need.
Breadth: High on the clinical axis (treating osteoporosis; any human; daily SQ; fixed 80 μg; fixed molecule).
Key narrowing variables: none in claim 1 besides dose, molecule, route, and regimen.
Claim 16 (independent)
- Same clinical backbone as claim 1, but adds that the composition is delivered in a multi-dose injection pen.
Breadth: Narrower than claim 1 because it requires the pen delivery format, but it targets a common commercial packaging choice for chronic osteoporosis dosing.
Claim 60 (independent)
- Adds a specific manufacturing/formulation process: dissolving peptide + antimicrobial + buffer in water to form a solution, then filtering through 0.2 μm.
Breadth: Narrower on process, but still independent. Companies using a different sterilization path or filter approach can avoid claim 60, while still potentially infringing claim 1 if they match the dose/route/molecule.
Claim 69 (independent)
- Adds a formulation achieving specified PK parameter targets (table-driven).
Breadth: High on “what the dosing regimen achieves,” not only on “what it is.” It can be implicated even if a competitor uses a different formulation as long as the resulting PK overlaps the claimed windows.
Claim 74 (independent)
- Similar PK-parameter targeting, but with a different PK set (Cmax/Tmax/AUC/t1/2 windows shown).
Breadth: Another independent PK envelope. Together, claims 69 and 74 create multiple “PK target” tracks.
How do the dependent claims narrow RE49444’s scope (buffer, pH, pen, antimicrobials)?
Buffer identity and pH windows (claims 2–15, 21–30, 64–68)
Dependent claims tightly define:
- pH: maintained between 2 and 7 (claim 2), refined progressively to about 5.1 (claim 15; also claims 22–23; 24–25; 64; 22–23 are about “about 5.1”).
- Buffer families: acetate, tartrate, phosphate, citrate (claim 3).
- Preferred buffer for later claim chain: acetate (claims 4; 27–29; 66–68).
- Acid/base pair: acetic acid and sodium acetate (claims 5; 30–32; 67).
- Sodium acetate hydrate form: sodium acetate trihydrate (claims 33–35; 68).
Design-around implication:
- If a competitor selects a different buffer system (not acetate/citrate as specified) or operates outside the ~5.1 pH target, they can reduce risk on these dependent claims.
- However, infringement can still occur under claim 1 (which does not require buffer) if the clinical/dose/molecule/route conditions are met.
Multi-dose injection pen packaging (claims 16, 78–79)
- Claim 16 limits the method to dosing “delivered in a multi-dose injection pen.”
- Claims 78 and 79 explicitly carry this forward for both claim families (claims 16 and 74).
Design-around implication:
- A competitor using a different device format (single-dose prefilled syringe, vial + needle, autoinjector with different architecture) can attempt to avoid the “multi-dose pen” limitation.
- But they would still need to address claim 1 and any PK-process independent claims that do not require the pen.
Antimicrobial package (claims 17–20, 36–53, 61–63)
The antimicrobial chain is highly specific:
- Antimicrobial present (claim 17).
- Antimicrobial selected from phenol, chlorocresol, methylparaben/propylparaben, or combinations (claim 18).
- Phenol selected (claim 19) and then 5 mg/mL phenol (claim 20; also claims 62–63).
- Microbial reduction limits:
- Bacteria: limit colony-forming units of S. aureus, P. aeruginosa, E. coli to < 5 cfu/mL at multiple timepoints (6 hours, 24 hours, 28 days) (claims 36–38; also claim structure 37–38).
- Yeast/mold: limit A. niger and C. albicans to < 5 cfu/mL at 7 days and 28 days (claims 45–47).
- Storage conditions prior to challenge:
- 3 months at 25°C (claims 39–41, 48–50).
- 4.5 months at 5°C (claims 42–44, 51–53).
Design-around implication:
- A competitor can avoid these dependent claims by using a different preservative system, concentration, or failing to satisfy the CFU reduction metrics and/or storage/stability-to-microbe challenge conditions.
- Again, claim 1 can still be asserted unless the litigation theory is limited to the dependent claims.
Where do the “PK target” claims sit, and how do they work legally?
Claim 69 PK table and windows
Claim 69 claims a method where the composition is formulated to achieve:
- Cmax: mean ± SD given (310 ± 54.3 pg/mL)
- Tmax: 0.251 (0.251, 1.01) hr (median with min-max)
- Tlast: 7.00 (4.00, 12.01) hr
- AUC0-t, AUC0-inf, AUC0-tau
- t1/2: 2.30 ± 0.715 hr
- Additional derived parameters: AUCR, CL/F, ln(Cmax), ln(AUC), etc.
Claim 70–73 then create specific sub-windows for:
- Cmax: 255.57–364.3 pg/mL or 367.2–504.8 pg/mL
- Tmax: 0.251–1.01 hr or 0.500–1.00 hr
- t1/2: 1.585–3.015 hr or 1.265–2.115 hr
- AUC(0-inf): 541.99–1569.21 pg h/mL (claim 73)
Claim 74 PK table and windows
Claim 74 claims another PK set:
- Cmax: 436 ± 68.8 pg/mL
- Tmax: 0.507 (0.500, 1.00) hr
- Tlast: 6.00 (4.00, 8.02) hr
- AUC0-t, AUC0-tau, t1/2: 1.69 ± 0.425 hr
- Claim 75–77 add corresponding windows for Cmax, Tmax, t1/2.
Legal take: These are product-by-result style limitations. For infringement, the sponsor/defendant can argue the competing product’s actual PK does not hit the windows; plaintiffs will typically map the competitor’s clinical or bridge study exposure data into the claimed ranges.
What is the formulation stability scope (claims 54–59)?
Claims 54–59 lock specific remaining concentration thresholds over time:
- At least 98.9% of initial concentration after 1 month at 25°C (claims 54, 57).
- At least 96.3% after 3 months at 25°C (claims 55, 58).
- At least 99.5% after 4.5 months at 5°C (claims 56, 59).
- The peptide is explicitly the same engineered PTHrP(1-34) analog.
Design-around implication:
- A competitor could potentially claim non-infringement on stability window-dependent claims if its formulation, storage, and shelf-life data show different degradation profiles or different endpoints used in its testing paradigm.
- But again, claim 1 does not require stability.
What manufacturing/process limitation is in RE49444?
Claim 60 requires:
- Dissolving the peptide + antimicrobial + buffer in water to form a solution
- Filtering the solution through a 0.2 micron filter
Dependent claims 61–63 fix antimicrobial selection (phenol) and concentration (5 mg/mL phenol). Claims 64–68 fix buffer selection (citrate/acetate) and acetate acid/base pair and sodium acetate trihydrate.
Design-around implication:
- If a competitor uses sterile filtration with a different nominal pore size, uses terminal sterilization, or uses a different filtration architecture before fill, they can aim to avoid this independent process claim.
How many separate claim “clusters” does RE49444 create, and what does that mean for risk?
RE49444 creates multiple independent or quasi-independent limitation clusters:
-
Clinical regimen with fixed dose and molecule
-
Clinical regimen plus device format
-
Clinical regimen plus specific PK target envelopes
- Claims 69 and 74 plus sub-windows 70–73 and 75–77
-
Clinical regimen plus formulation process
-
Formulation composition narrowing
- pH/buffer family and acetate-specific detail (claims 2–15, 21–35)
-
Preservative system and microbiological efficacy metrics
- antimicrobial selection and CFU limits across bacteria/yeast/mold and storage conditions (claims 17–20; 36–53; 61–63)
-
Stability shelf-life performance
- remaining concentration thresholds (claims 54–59)
Risk consequence: a generic or biosimilar-like entrant must navigate not only dose/molecule/route, but also any one or more of these additional “clusters,” depending on the asserted claims in the litigation.
What patents protect the same therapeutic space around RE49444 (US litigation and exclusivity mechanics)?
The scope you provided identifies only the reissue patent number and its claims, not:
- the listed original patent(s) that RE49444 reissued from,
- the application/assignee history,
- the full family including continuation or related patents,
- the FDA product code and Orange Book identifiers,
- any co-pending or granted method-of-use/formulation/device patents in the same estate.
Given those gaps, a complete “US patent landscape” across related granted patents, continuations, and the Orange Book set cannot be produced without introducing uncited or non-verifiable items.
How would a generic entry risk be analyzed against these specific claims?
Even without external records, the claim language implies three primary infringement theories a plaintiff could pursue:
1) Direct method infringement under claim 1
A competitor launching a product that matches:
- 80 μg daily SQ dosing
- the specified peptide identity
- osteoporosis treatment in humans
…creates baseline risk. Buffer choice, antimicrobial choice, and device can be irrelevant if claim 1 is asserted alone.
2) Dependent-claim strengthening via formulation and PK windows
If the competing product’s dosing regimen and formulation deliver exposure profiles matching the Cmax/Tmax/t1/2/AUC windows, claim 69/74 may be asserted to capture “by-result” performance. This is often the fastest way to avoid disputes about device or preservative choices.
3) Additional hooks via pen format, antimicrobial CFU metrics, and 0.2 μm filtration
Competitors can reduce risk by:
- selecting a non-pen multi-dose delivery,
- using a different preservative package or concentration not meeting CFU constraints,
- using different filtration/processing steps to avoid the 0.2 μm requirement,
- choosing stability profiles that do not meet the remaining concentration thresholds.
But these defenses only matter against the corresponding dependent claims.
Key Takeaways
- RE49444 claim scope is built around daily subcutaneous 80 μg dosing of a specific engineered hPTHrP(1-34) analog for osteoporosis, with major additional coverage layers for buffer/pH (~5.1, acetate-specific), pen delivery, phenol antimicrobial (5 mg/mL) and CFU efficacy metrics, stability, a 0.2 μm filtration process, and PK target windows (Cmax/Tmax/t1/2 and AUC ranges).
- The estate’s litigation leverage typically comes from two axes: (i) claim 1’s fixed regimen and molecule and (ii) claims 69/74’s PK-target “product-by-result” limitations.
- Practical around-design strategies focus on separating variables tied to dependent claims (device, preservative, filtration, stability), but cannot fully eliminate risk if claim 1 matches the active ingredient and regimen.
FAQs
-
Can a competitor avoid RE49444 if they change from a multi-dose pen to a different delivery device?
Avoidance may reduce exposure to pen-dependent claims (claim 16, 78–79) but does not address claim 1 unless the regimen and dose/molecule/route are also changed.
-
Do buffer and antimicrobial choices matter if claim 1 is asserted?
Not for claim 1, because claim 1 does not require specific buffer or antimicrobial limitations. They matter mainly for dependent claims.
-
How does infringement analysis work for the PK-window claims (69 and 74)?
The competitor’s formulation and dosing must produce PK parameters that fall within the claimed windows, using test/clinical data mapped to the Cmax/Tmax/t1/2/AUC ranges.
-
Does the 0.2 μm filtration requirement create a clear manufacturing “design-around”?
Yes for claim 60, if the competitor uses a different filtration pore size or process that does not include filtering through a 0.2 μm filter as claimed.
-
Are stability metrics enforceable as standalone infringement triggers?
They are enforceable to the extent the corresponding stability-dependent claims (54–59) are asserted and the competitor’s product fails the “% remaining after time/temp” thresholds.
References
No external sources were provided or cited in the prompt.
